Related Experiment Video

Updated: Aug 15, 2026

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
12:04

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy

Published on: August 14, 2012

Short-term treatment of short stature and subnormal growth rate with human growth hormone

S Raiti, S L Kaplan, G Van Vliet

    The Journal of Pediatrics
    |March 1, 1987
    PubMed

    Insights

    Exogenous human growth hormone (hGH) significantly increased growth rates in children with short stature. Continued hGH therapy appears necessary to maintain these elevated growth rates.

    Area of Science:

    • Pediatrics
    • Endocrinology
    • Growth Hormone Therapy

    Background:

    • Short stature in children can impact physical and psychological development.
    • Normal growth hormone response to secretagogues indicates the pituitary can produce GH, but release or action may be impaired.

    Purpose of the Study:

    • To evaluate the short-term efficacy of exogenous human growth hormone (hGH) in children with short stature and normal GH response.
    • To determine if growth rate increases are sustained after hGH therapy cessation.

    Main Methods:

    • Forty-eight children with short stature received hGH therapy for 6 months.
    • Growth rates were measured before, during, and after hGH treatment.
    • Some children received an additional 6 months of hGH therapy.

    Main Results:

    • hGH therapy significantly increased mean growth rate from 3.4 cm/yr to 6.9 cm/yr.
    • After treatment cessation, growth rates decreased but often remained above baseline.
    • Resuming hGH therapy in a subset of children again increased their growth rate.

    Conclusions:

    • Exogenous hGH effectively enhances short-term growth in children with short stature and normal GH secretion.
    • Sustained growth acceleration appears dependent on continuous hGH administration.

    More Related Videos

    Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays11:17

    Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

    Published on: January 7, 2016

    Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies06:24

    Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

    Published on: January 10, 2025

    Related Concept Videos

    Nature and Nurture01:10

    Nature and Nurture

    Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
    Gene Therapy00:59

    Gene Therapy

    Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

    Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
    ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
    Insulin: Dosing Regimen and Adverse Effects01:16

    Insulin: Dosing Regimen and Adverse Effects

    Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
    The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
    Hypoglycemia and Glucagon01:15

    Hypoglycemia and Glucagon

    Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...